Implementation of high-throughput screening for Fabry disease in Toronto dialysis patients
Notice bibliographique
Résumé
Sir, Fabry disease is a rare X-linked lysosomal storage disorder caused by mutations in the α-galactosidase A (α-gal A) gene. Affected hemizygous males have impaired or abrogated activity of α-gal A enzyme that leads to a buildup of neutral glycosphingolipids, particularly globotriaosylceramide (Gb3), in many tissues and organs [1]. Symptoms include acroparesthesias, angiokeratomas, corneal opacities, and cardiovascular and renal complications, with death usually occurring by the fifth decade of life [1]. Females that are heterozygous carriers of an α-gal A enzyme mutation show a wide variety in the range and severity of their symptoms. The kidney is of particular pathological importance in Fabry disease, as kidney failure due to Gb3 buildup is a major complication; along with cardiac failure it is a leading cause of death [2]. In recent years, it has been proposed that some dialysis patients could be suffering from undiagnosed Fabry disease and therefore there would be benefits to screening dialysis patients for this disease [3,4]. We carried out a pilot screening study at the Toronto General Hospital in Ontario, Canada, to implement our previously published high-throughput blood spot assay for Fabry disease [5]. Informed consent was obtained from 147 forthcoming. dialysis patients to screen their blood for levels of α-gal A enzyme. Based on our blood spot assay, 141 of these patients had whole blood α-gal A enzyme activity levels within the normal range compared to normal and Fabry controls [5, and unpublished data]. For those six patients with activity below 1.5 nmol/h/ml (<65% of average enzyme activity in normal controls), secondary plasma α-gal A enzyme assays showed that all patients were within the normal range. While no Fabry patients were identified in the relatively small participating patient population, this study shows application of our previously published high-throughput screening method. Our assay is a rapid and low-cost method for screening patients that may be suffering from undiagnosed Fabry disease. This initial screening study did not exclude any patients willing to participate, so both males and females were included. As with other symptoms, α-gal A enzyme levels in female Fabry patients vary with the individual and can even approach normal levels. We thus cannot discount the possibility that there remain undiagnosed female Fabry patients in this population. For this male dialysis population. With the availability of enzyme replacement therapy (ERT) for lysosomal storage disorders such as Fabry disease, standardized screening for particular biomarkers is beginning to be considered a useful tool for diagnostics [6]. Future screening studies may help to identify Fabry patients that would gain immediate benefit from diagnosis. Screening for this disease is particularly timely in Canada, where a comparative clinical trial of currently approved ERT drugs is ongoing. We would like to thank the patients and the staff at the UHN dialysis clinic for their participation in this study, and Armando Poeppl for technical assistance. This study was sponsored in part by an NIH grant to JAM (HL0569); sample collection and analyses were supported by Genzyme Canada Inc.; Genzyme had no role in the interpretation of results and had no access to individual patient data. Conflict of interest statement. None declared.
Récupéré en direct depuis OpenAlex et désinversé. Les résumés ne sont pas conservés dans cette base de données : les index inversés représentent 8,6 Go des 9,3 Go de texte de la base, et le serveur dispose de 13 Go libres.
Comment cette classification a été obtenuedéplier
Prédiction distillée sur la base complète
Imitation des enseignantsNi prévalence calibrée, ni vérité terrain. Validation humaine à venir. Apprise à partir de 10 348 étiquettes directes de Codex et de 10 348 étiquettes directes de Gemma. Le mode candidate est l'union des têtes enseignantes seuillées; le consensus est leur intersection. Ces sorties portent le statut machine_predicted_unvalidated et ne sont ni des étiquettes humaines ni des étiquettes directes de modèles de pointe.
Scores Codex et Gemma par catégorie
| Catégorie | Codex | Gemma |
|---|---|---|
| Métarecherche | 0,001 | 0,004 |
| Méta-épidémiologie (sens strict) | 0,000 | 0,000 |
| Méta-épidémiologie (sens large) | 0,000 | 0,000 |
| Bibliométrie | 0,000 | 0,000 |
| Études des sciences et des technologies | 0,000 | 0,000 |
| Communication savante | 0,000 | 0,000 |
| Science ouverte | 0,000 | 0,000 |
| Intégrité de la recherche | 0,000 | 0,000 |
| Charge utile insuffisante (le modèle a refusé de juger) | 0,001 | 0,000 |
Scores machine (provisoires)
Les deux têtes enseignantes du modèle étudiant, lues sur ce travail. Un score ordonne la base pour la relecture; il n'affirme jamais une catégorie, et le statut de validation accompagne chaque rangée tel quel.
Scores de référence d'un modèle non mature (critères de maturité non atteints, 7 itérations). Un score ordonne; il n'affirme jamais une catégorie.
score_only:v0-immature-baseline · tel quel depuis la passe de notation : score_only signifie que le nombre peut ordonner les travaux, et qu'aucune étiquette de catégorie n'en découleClassification
machine, non validéePrédiction automatique; un appel candidat d’une seule tête enseignante, pas un consensus.
Le détail, modèle par modèle et score par score, se trouve en fin de page sous « Comment cette classification a été obtenue ».